Cognition Therapeutics Inc CGTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.26
- Day Range
- $1.25–1.48
- 52-Week Range
- $0.25–3.83
- Bid/Ask
- $1.41 / $1.42
- Shares Outstanding
- 89.50M
- Market Cap
- $127.09M
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 14
- Website
- https://www.cogrx.com
Valuation
|
Metric
|
CGTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.61 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CGTX
|
|---|---|
Quick Ratio | 5.75 |
Current Ratio | 5.92 |
Interest Coverage | −1,504.92 |
Quick Ratio
CGTX
Profitability
|
Metric
|
CGTX
|
|---|---|
Return on Assets (Normalized) | −51.87% |
Return on Equity (Normalized) | −73.94% |
Return on Invested Capital (Normalized) | −72.32% |
Return on Assets
CGTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Ftgwblzz | Bcwzklx | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vfhfxgbw | Ytdcp | $64B | |||
| argenx SE ADR
ARGX
| Sllwzjmdd | Jrdll | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Pqbmplsch | Qykxdx | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Lswthgszv | Kxcqgd | $24B | |||
| BioNTech SE ADR
BNTX
| Nllqsqjm | Mgyxl | $23B | |||
| Incyte Corp
INCY
| Rzfwlqn | Zwqr | $22B | |||
| Moderna Inc
MRNA
| Zdyrwlh | Lxsg | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Vnldnbv | Pfg | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Cwxvchdyl | Zlw | $13B |
United States